Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 2 2

Status

Completed 5

Sponsor Class

OTHER 2INDUSTRY 2NETWORK 1

Study Type

Interventional 5

Sponsor

Cancer Type

Dermatologic 5

Conditions

Leukemia, Promyelocytic, Acute 27Leukemia, Myeloid, Acute 27Leukemia 16Myelodysplastic Syndromes 13Multiple Myeloma 9Neuroblastoma 5Melanoma 5Lung Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Pancreatic Neoplasms 4Neoplasm Metastasis 4Myeloproliferative Disorders 4Myelodysplastic-Myeloproliferative Diseases 4Leukemia, Myelomonocytic, Acute 4Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 4Leukemia, Monocytic, Acute 4Leukemia, Megakaryoblastic, Acute 4Leukemia, Erythroblastic, Acute 4Hematologic Neoplasms 4Congenital Abnormalities 4Uterine Cervical Neoplasms 3Leukemia, Myelomonocytic, Chronic 3Anemia, Refractory, with Excess of Blasts 3Thrombocytopenia 2Small Cell Lung Carcinoma 2Prostatic Neoplasms 2Primary Myelofibrosis 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pathologic Complete Response 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2

Interventions

pembrolizumab 287Nivolumab 258Ipilimumab 236Cyclophosphamide 135aldesleukin 134Interleukin-2 104Temozolomide 75Dacarbazine 74trametinib 70Vemurafenib 69fludarabine 68dabrafenib 65fludarabine phosphate 62sargramostim 44binimetinib 44Radiosurgery 44Biopsy 43Paclitaxel 42Bevacizumab 42incomplete Freund's adjuvant 39encorafenib 37Radiotherapy 36Cisplatin 36CTLA-4 Antigen 36atezolizumab 35Carboplatin 35Magnetic Resonance Spectroscopy 33cobimetinib 32Specimen Handling 31Introns 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × Melanoma × Tretinoin × Clear all
NCT04303169 2025-10-27

KEYMAKER-U02

Merck Sharp & Dohme LLC

Phase 1/2 Completed
146 enrolled
Dermatologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT04305041 2025-08-29

KEYMAKER-U02

Merck Sharp & Dohme LLC

Phase 1/2 Completed
100 enrolled
Dermatologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT03200847 2024-10-01

Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma

University of Colorado, Denver

Phase 1/2 Completed
26 enrolled 13 charts
Dermatologic

Melanoma

NCT02403778 2023-09-21

Ipilimumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma

University of Colorado, Denver

Phase 2 Completed
10 enrolled 12 charts
Dermatologic

Melanoma

NCT00003601 2023-06-18

Tretinoin With or Without Fenretinide in Treating Patients With Dysplastic Nevus Syndrome

Eastern Cooperative Oncology Group

Phase 2 Completed
38 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡